Titan Biotech Ltd
524717Titan Biotech Ltd's price has outrun its earnings. +365.8% in a year against EPS +38.8% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +365.8% in a year while annual EPS moved +38.8% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (44 weeks in) while the P/E sits at the 96th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +66.2% year on year, and 92% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Titan Biotech Ltd trades at ₹425, in a confirmed uptrend and 44 weeks into that stage. That is +29.3% against its own 200-day average. It sits at 78% of a 52-week range of ₹139 to ₹504. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (9 weeks and counting).
Today the stock is in a confirmed uptrend — week 44 of stage 2, confirmed. At ₹425 it trades +29.3% versus its 200-day average and sits at 78% of its 52-week range (₹139–₹504).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +5,657% while the NIFTY 500 moved +280% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (9 weeks and counting; last ahead the week of 2026-06-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 96th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Titan Biotech Ltd trades at 57.5× P/E, at the pricey end of its own range (96th percentile). Its long-run median P/E is 12.6×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 57.5× is at the pricey end of its own range (96th percentile), against a long-run median of 12.6× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +38.8% against a +365.8% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +43.8%/yr price move, ~−0.5%/yr came from earnings growth and ~+44.3 pp from the multiple (expanding); over 10y, of the +50.9%/yr price move, ~+31.7%/yr came from earnings growth and ~+19.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Titan Biotech Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −19.0% at the trough to +66.2% off a 4-quarter-old trough (single-quarter readings), ROCE holding at 23.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +32.1% | +12.7% | +7.7% | +16.2% |
| Profit | +36.4% | +6.3% | −1.3% | +31.1% |
| EPS | +38.8% | +6.4% | −0.3% | +31.7% |
| Share price | +365.8% | +103.3% | +43.8% | +50.9% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
68.8/100 — rank 2 of 24 in Pesticides/Agrochemicals · 79% evidence confidence
Titan Biotech Ltd scores 68.8 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 2. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 29.1 + 20.1 + 5.6 + 14 = 68.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Titan Biotech Ltd reported ₹48.8 Cr of revenue in the Mar 26 quarter, +38.8% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 16.2% a year. The last full year, FY26, came in at ₹206 Cr. The last four reported quarters add to ₹206 Cr.
Titan Biotech Ltd reported ₹48.8 Cr of revenue in the Mar 26 quarter, +38.8% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 16.2% a year. The last full year, FY26, came in at ₹206 Cr. The last four reported quarters add to ₹206 Cr.
FY26 revenue came in at ₹206 Cr (+32.1% on the year), capping 10 years at 16.2% compound. The latest quarter (Mar 26) printed ₹48.8 Cr, +38.8% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +32.6% growth against the decade's 16.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +31.8% over the last 4 quarters against +12.1%/yr over the last 8 — accelerating; TTM profit +38.7% vs +9.7%/yr — accelerating.
→ Revenue grew — did margins hold as it scaled? Next: 19.9% this quarter (+6.9 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Titan Biotech Ltd's operating margin is 19.9% in the Mar 26 quarter, +6.9 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 9.0% to 32.0%. The current quarter sits inside that band.
Titan Biotech Ltd's operating margin is 19.9% in the Mar 26 quarter, +6.9 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 9.0% to 32.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 19.9%, +6.9 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 9.0%–32.0%.
Why the margin moved: operating margin went +6.9 pp year on year while gross margin went +4.1 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins held — did that reach the bottom line? Next: profit +66.2% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Titan Biotech Ltd earned ₹6.7 Cr of net profit in the Mar 26 quarter, +66.2% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹30.0 Cr. The 10-year compound rate is 31.1%. That is 13.8% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr.
Titan Biotech Ltd earned ₹6.7 Cr of net profit in the Mar 26 quarter, +66.2% year on year. It is the 4th consecutive quarter of growth. Full-year FY26 profit was ₹30.0 Cr. The 10-year compound rate is 31.1%. That is 13.8% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr.
Mar 26 profit was ₹6.7 Cr, +66.2% year on year — the 4th consecutive quarter of growth. On the full year, FY26 printed ₹30.0 Cr (+36.4%), and the 10-year compound rate is 31.1%.
Why profit moved: revenue contributed +38.8% and the margin +6.9 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +45.9% vs revenue +32.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 92% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 92% of Titan Biotech Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹30.0 Cr of operating cash against ₹30.0 Cr of profit. After ₹10.0 Cr of capital spending, ₹20.0 Cr was left as free cash.
FY26: operating cash of ₹30.0 Cr against reported profit of ₹30.0 Cr, leaving free cash of ₹20.0 Cr after ₹10.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 92% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 92%: the cash cycle stretched 17 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 2.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹27.0 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Titan Biotech Ltd's cash conversion cycle runs 220 days in FY26, up from 203 days in FY21. Capital spending ran ₹27.0 Cr over the last 3 years. At FY26 sales of ₹206 Cr each day of that cycle holds about ₹0.6 Cr, so roughly ₹124 Cr sits inside the business at any moment.
FY26: debtors at 40 days, inventory at 212 days — roughly 7.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 220 days, looser than FY21's 203.
The full loop: cash goes out to suppliers and production on day 0; stock waits 212 days to sell; customers pay about 40 days after that; and suppliers themselves are paid at 32 days — netting out to the 220-day cycle.
In money terms: at FY26 sales of ₹206 Cr, each day of the cycle holds about ₹0.6 Cr — so the 220-day loop keeps roughly ₹124 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹27.0 Cr over the last 3 fiscal years against ₹12.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 23%.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Titan Biotech Ltd earns a ROCE of 23% in FY26. That is up from a trough of 12% in FY16. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 14.6% net margin on 0.96× asset turns.
FY26 ROCE is 23%, recovered from a FY16 trough of 12% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 14.6% net margin × 0.96× asset turns × 1.18× balance-sheet leverage ≈ 16.5% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.03.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Titan Biotech Ltd carries ₹6.0 Cr of borrowings against ₹181 Cr of equity in FY26, a debt-to-equity of 0.03. Operating profit covers the interest bill 39×. Over 5 years borrowings went from ₹16.0 Cr to ₹6.0 Cr. Capital spending ran ₹27.0 Cr across the last 3 of those years.
FY26: borrowings of ₹6.0 Cr against equity of ₹181 Cr — a debt-to-equity of 0.03. Operating profit covers the interest bill 39×. Over 5 years borrowings went from ₹16.0 Cr to ₹6.0 Cr while capital spending ran ₹27.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
→ Who owns this, and are they adding or leaving? Next: the register is quiet.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Titan Biotech Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.0 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −0.1 points over 8 quarters to 55.8%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Titan Biotech Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Titan Biotech Ltd this page | 57.5× | ₹1,719 Cr | Turning around | |||
| UPL Ltd | 28.2× | ₹50,841 Cr | No read | |||
| P I Industries Ltd | 34.5× | ₹41,437 Cr | Deteriorating | |||
| Sumitomo Chemical India Ltd | 50.9× | ₹25,978 Cr | Mixed | |||
| Bayer CropScience Ltd | 385.0× | ₹18,954 Cr | — | — | — | — |
| Jubilant Ingrevia Ltd | 36.3× | ₹11,557 Cr | Mixed | |||
| Sharda Cropchem Ltd | 12.1× | ₹7,876 Cr | Mixed | |||
| Epigral Ltd | 15.2× | ₹5,016 Cr | Mixed | |||
| NACL Industries Ltd | 178.0× | ₹4,610 Cr | No read | |||
| Dhanuka Agritech Ltd | 15.5× | ₹4,517 Cr | Topping out | |||
| Rallis India Ltd | 26.9× | ₹4,253 Cr | Mixed | |||
| Bhagiradha Chemicals & Industries Ltd | 188.0× | ₹3,416 Cr | Improving | |||
| GSP Crop Science Ltd | 24.4× | ₹2,468 Cr | — | — | — | — |
| Bharat Rasayan Ltd | 13.1× | ₹2,096 Cr | Mixed | |||
| Insecticides India Ltd | 12.9× | ₹1,793 Cr | Mixed | |||
| India Pesticides Ltd | 14.4× | ₹1,727 Cr | Mixed | |||
| Astec Lifesciences Ltd | — | ₹1,469 Cr | No read | |||
| Meghmani Organics Ltd | 48.2× | ₹1,385 Cr | No read | |||
| Punjab Chemicals & Crop Protection Ltd | 21.0× | ₹1,375 Cr | Mixed | |||
| Excel Industries Ltd | 15.5× | ₹1,172 Cr | Mixed | |||
| Titan Biotech Ltd | 42.0× | ₹1,141 Cr | Turning around | |||
| Dharmaj Crop Guard Ltd | 16.1× | ₹882 Cr | No read | |||
| Advance Agrolife Ltd | 20.0× | ₹706 Cr | No read | |||
| Heranba Industries Ltd | — | ₹700 Cr | No read | |||
| Best Agrolife Ltd | 60.6× | ₹538 Cr | No read |
Frequently asked questions
What is Titan Biotech Ltd's share price today?
Titan Biotech Ltd trades at ₹425, +365.8% over the past year. The company is valued at ₹1,719 Cr. The stock sits at 78% of its 52-week range of ₹139–₹504, +29.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 44 weeks in. — as of 24 July 2026.
What were Titan Biotech Ltd's latest quarterly results?
Titan Biotech Ltd reported revenue of ₹48.8 Cr and net profit of ₹6.7 Cr for the Mar 26 quarter. Revenue rose 38.8% and profit rose 66.2% year on year. Earnings per share were ₹1.63. The operating margin was 19.9%, 6.9 pp higher than a year earlier. — as of 24 July 2026.
What is Titan Biotech Ltd's revenue?
Titan Biotech Ltd reported revenue of ₹48.8 Cr in the Mar 26 quarter, +38.8% year on year. For the full FY26 fiscal year, revenue was ₹206 Cr (+32.1%). Over the last 10 years revenue compounded at 16.2% a year. — as of 24 July 2026.
What is Titan Biotech Ltd's profit?
Titan Biotech Ltd earned ₹6.7 Cr of net profit in the Mar 26 quarter, +66.2% year on year — the 4th straight quarter of growth. Full-year FY26 profit was ₹30.0 Cr. The operating margin ran 19.9% in the latest quarter. — as of 24 July 2026.
What is Titan Biotech Ltd's market cap?
Titan Biotech Ltd's market capitalisation is ₹1,719 Cr at a share price of ₹425. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Titan Biotech Ltd's P/E ratio?
Titan Biotech Ltd trades at a P/E of 57.5×, at the 96th percentile of its own 10-year range, against a long-run median of 12.6×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Titan Biotech Ltd pay a dividend?
Yes — Titan Biotech Ltd's dividend payout was 7% of profit in FY26, and it recorded a payout in 11 of its last 12 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Titan Biotech Ltd overvalued?
On its own history, Titan Biotech Ltd looks expensive against its own history: its P/E of 57.5× sits at the 96th percentile of its 10-year range (long-run median 12.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Titan Biotech Ltd growing?
Yes — Titan Biotech Ltd is growing: latest-quarter revenue +38.8% year on year, profit +66.2%, and the margin +6.9 pp at 19.9%. The 10-year compound rates are 16.2% (revenue) and 31.1% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Titan Biotech Ltd performing?
Titan Biotech Ltd is in a confirmed uptrend, 44 weeks in. Its latest quarter's revenue rose 38.8% and profit rose 66.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Titan Biotech Ltd in?
Turning around — profit growth swung from −19.0% at the trough to +66.2% off a 4-quarter-old trough (single-quarter readings), ROCE holding at 23.0%. The read comes from the last 12 quarters of growth (revenue growth +38.8% latest, profit growth +66.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Titan Biotech Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 44 of stage 2), trading +29.3% versus its 200-day average and at 78% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Titan Biotech Ltd beating the market?
Not lately — on a trailing-13-week view Titan Biotech Ltd is currently behind the NIFTY 500 (9 weeks and counting; last ahead the week of 2026-06-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +5,657% against the NIFTY 500's +280% — ahead of the index over the full window. — as of 24 July 2026.
Will Titan Biotech Ltd's share price go up?
This page publishes no price forecast for Titan Biotech Ltd. What it measures instead: the share price is ₹425, the price is in a confirmed uptrend 44 weeks in. Its P/E of 57.5× sits at the 96th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Titan Biotech Ltd?
Promoters hold 55.8% of Titan Biotech Ltd, foreign institutions null%, domestic institutions 0.0% and the public 44.2% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 24 July 2026.
Does Titan Biotech Ltd have too much debt?
No — Titan Biotech Ltd's debt-to-equity is 0.03, and operating profit covers the interest bill 39×. FY26 borrowings were ₹6.0 Cr against equity of ₹181 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Titan Biotech Ltd's capex?
Titan Biotech Ltd spent ₹27.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹10.0 Cr, with ₹2.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Titan Biotech Ltd's cash flow?
Titan Biotech Ltd generated ₹30.0 Cr of operating cash flow in FY26 and ₹20.0 Cr of free cash flow after ₹10.0 Cr of capital spending. Reported profit that year was ₹30.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Titan Biotech Ltd's profit real cash?
Yes — over the last 3 fiscal years, 92% of Titan Biotech Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹30.0 Cr against reported profit of ₹30.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Titan Biotech Ltd in its business cycle?
Titan Biotech Ltd's FY26 operating margin was 19.0%, against a 12-year band of 9.0%–32.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 19.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Titan Biotech Ltd story?
The sharpest disagreement: the price moved +365.8% in a year while annual EPS moved +38.8% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Titan Biotech Ltd a stock worth studying right now?
This is not investment advice. The machine read: Titan Biotech Ltd's price has outrun its earnings. +365.8% in a year against EPS +38.8% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.